Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIC: Infliximab and Azathioprine in Crohn's Disease
NCT00094458Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Mar 2005
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of infliximab in Crohn's disease (3 arms), sponsored by Janssen Biotech. Primary endpoint: Percentage of Participants With Corticosteroid-free Clinical Remission at 26 weeks. Started Mar 2005; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00094458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094458.